Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Revenue (2016 - 2025)

Historic Revenue for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $799.5 million.

  • United Therapeutics' Revenue rose 675.66% to $799.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 1129.99%. This contributed to the annual value of $2.9 billion for FY2024, which is 2362.62% up from last year.
  • As of Q3 2025, United Therapeutics' Revenue stood at $799.5 million, which was up 675.66% from $798.6 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Revenue ranged from a high of $799.5 million in Q3 2025 and a low of -$7.9 million during Q4 2024
  • Moreover, its 5-year median value for Revenue was $506.9 million (2023), whereas its average is $519.0 million.
  • Over the last 5 years, United Therapeutics' Revenue had its largest YoY gain of 3369.5% in 2024, and its largest YoY loss of 89000.0% in 2024.
  • United Therapeutics' Revenue (Quarter) stood at $415.2 million in 2021, then rose by 18.38% to $491.5 million in 2022, then crashed by 99.8% to $1.0 million in 2023, then plummeted by 890.0% to -$7.9 million in 2024, then skyrocketed by 10220.25% to $799.5 million in 2025.
  • Its Revenue was $799.5 million in Q3 2025, compared to $798.6 million in Q2 2025 and $794.4 million in Q1 2025.